PROGNOSTIC MARKERS OF DNA METHYLATION AND NGS SEQUENCING IN PROGRESSIVE GLIOBLASTOMA FROM THE EORTC-26101 TRIAL

被引：0
|
作者：
Kessler, T. [1 ]
Schrimpf, D. [1 ]
Doerner, L. [1 ]
Hai, L. [1 ]
Kaulen, L. [1 ]
Ito, J. [1 ]
van den Bent, M. [2 ]
Taphoorn, M. [3 ]
Brandes, A. A. [4 ]
Idbaih, A. [5 ]
Domont, J. [6 ]
Clement, P. M. [7 ]
Campone, M. [8 ]
Bendszus, M. [1 ]
von Deimling, A. [1 ]
Sahm, F. [1 ]
Platten, M. [9 ]
Wick, W. [1 ]
Wick, A. [1 ]
机构：
[1] Heidelberg Univ Hosp, Heidelberg, Germany
[2] Erasmus MC Canc Inst, Rotterdam, Netherlands
[3] Leiden Univ Med Ctr, Leiden, Netherlands
[4] Azienda Unita Sanitaria Locale Bologna, Bologna, Italy
[5] Sorbonne Univ, Paris, France
[6] Inst Gustave Roussy, Villejuif, France
[7] Katholieke Univ Leuven, Leuven, Belgium
[8] Ctr Rene Gauducheau, St Herblain, France
[9] Med Fac Mannheim, Mannheim, Germany
来源：
NEURO-ONCOLOGY | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P05.01.B
引用
收藏
页数：1
相关论文
共 19 条
  • [1] Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
    Kessler, Tobias
    Schrimpf, Daniel
    Doerner, Laura
    Hai, Ling
    Kaulen, Leon D.
    Ito, Jakob
    van den Bent, Martin
    Taphoorn, Martin
    Brandes, Alba A.
    Idbaih, Ahmed
    Domont, Julien
    Clement, Paul M.
    Campone, Mario
    Bendszus, Martin
    von Deimling, Andreas
    Sahm, Felix
    Platten, Michael
    Wick, Wolfgang
    Wick, Antje
    CLINICAL CANCER RESEARCH, 2023, 29 (19) : 3892 - 3900
  • [2] TEMPORAL MUSCLE THICKNESS IS AN INDEPENDENT PROGNOSTIC MARKER IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA: TRANSLATIONAL IMAGING ANALYSIS OF THE EORTC-26101 TRIAL
    Furtner, J.
    Genbrugge, E.
    Gorlia, T.
    Bendszus, M.
    Nowosielski, M.
    Golfinopoulos, V.
    Weller, M.
    van den Bent, M. J.
    Wick, W.
    Preusser, M.
    NEURO-ONCOLOGY, 2019, 21 : 76 - 76
  • [3] Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial
    Furtner, Julia
    Genbrugge, Els
    Gorlia, Thierry
    Bendszus, Martin
    Nowosielski, Martha
    Golfinopoulos, Vassilis
    Weller, Michael
    Van den Bent, Martin J.
    Wick, Wolfgang
    Preusser, Matthias
    NEURO-ONCOLOGY, 2019, 21 (12) : 1587 - 1594
  • [4] Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial
    Schell, Marianne
    Pflueger, Irada
    Brugnara, Gianluca
    Isensee, Fabian
    Neuberger, Ulf
    Foltyn, Martha
    Kessler, Tobias
    Sahm, Felix
    Wick, Antje
    Nowosielski, Martha
    Heiland, Sabine
    Weller, Michael
    Platten, Michael
    Maier-Hein, Klaus H.
    Von Deimling, Andreas
    van den Bent, Martin J.
    Gorlia, Thierry
    Wick, Wolfgang
    Bendszus, Martin
    Kickingereder, Philipp
    NEURO-ONCOLOGY, 2020, 22 (11) : 1667 - 1676
  • [5] DNA methylation and protein expression of Wnt pathway markers in progressive glioblastoma
    Tompa, Marton
    Kajtar, Bela
    Galik, Bence
    Gyenesei, Attila
    Kalman, Bernadette
    PATHOLOGY RESEARCH AND PRACTICE, 2021, 222
  • [6] Corticosteroids use and neurocognitive functioning in patients with recurrent glioblastoma: Evidence from European Organization for Research and Treatment of Cancer (EORTC) trial 26101
    Caramanna, Ivan
    de Kort, Julie M.
    Brandes, Alba A.
    Taal, Walter
    Platten, Michael
    Idbaih, Ahmed
    Frenel, Jean Sebastien
    Wick, Wolfgang
    Preetha, Chandrakanth Jayachandran
    Bendszus, Martin
    Vollmuth, Philipp
    Reijneveld, Jaap C.
    Klein, Martin
    NEURO-ONCOLOGY PRACTICE, 2022, 9 (04) : 310 - 316
  • [7] Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial
    Draaisma, Kaspar
    Tesileanu, C. Mircea S.
    de Heer, Iris
    Klein, Martin
    Smits, Marion
    Reijneveld, Jaap C.
    Clement, Paul M.
    de Vos, Filip Y. F.
    Wick, Antje
    Mulholland, Paul J.
    Taphoorn, Martin J. B.
    Weller, Michael
    Chinot, Olivier L.
    Kros, Johan M.
    Verschuere, Tina
    Coens, Corneel
    Golfinopoulos, Vassilis
    Gorlia, Thierry
    Idbaih, Ahmed
    Robe, Pierre A.
    van den Bent, Martin J.
    French, Pim J.
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2440 - 2448
  • [8] MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial
    Weller, Michael
    Tabatabai, Ghazaleh
    Kaestner, Baerbel
    Felsberg, Joerg
    Steinbach, Joachim P.
    Wick, Antje
    Schnell, Oliver
    Hau, Peter
    Herrlinger, Ulrich
    Sabel, Michael C.
    Wirsching, Hans-Georg
    Ketter, Ralf
    Baehr, Oliver
    Platten, Michael
    Tonn, Joerg C.
    Schlegel, Uwe
    Marosi, Christine
    Goldbrunner, Roland
    Stupp, Roger
    Homicsko, Krisztian
    Pichler, Josef
    Nikkhah, Guido
    Meixensberger, Juergen
    Vajkoczy, Peter
    Kollias, Spyros
    Huesing, Johannes
    Reifenberger, Guido
    Wick, Wolfgang
    CLINICAL CANCER RESEARCH, 2015, 21 (09) : 2057 - 2064
  • [9] O6-methylguanine DNA methyltransferase gene promoter methylation status in glioblastoma and its correlation with other prognostic markers
    Sung Hak Lee
    Suk Woo Nam
    Yong Gil Hong
    Chang Suk Kang
    Youn Soo Lee
    Molecular & Cellular Toxicology, 2011, 7 : 425 - 430
  • [10] O6-methylguanine DNA methyltransferase gene promoter methylation status in glioblastoma and its correlation with other prognostic markers
    Lee, Sung Hak
    Nam, Suk Woo
    Hong, Yong Gil
    Kang, Chang Suk
    Lee, Youn Soo
    MOLECULAR & CELLULAR TOXICOLOGY, 2011, 7 (04) : 425 - 430
12